Status:
COMPLETED
Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children
Lead Sponsor:
Makerere University
Conditions:
Pneumonia
Eligibility:
All Genders
6-59 years
Phase:
PHASE3
Brief Summary
Acute lower respiratory tract infections are a leading cause of morbidity and mortality in sub Saharan Africa. The World Health Organisation (WHO) still recommends intravenous chloramphenicol for the ...
Detailed Description
A recent report from the World health Organization showed pneumonia was the leading cause of death in children less than 5 years. WHO recommends intravenous Chloramphenicol 25mg/kg six hourly as the f...
Eligibility Criteria
Inclusion
- Children aged 6 months to 59months with cough, difficult breathing and lower chest indrawing
- Consent from parent/carer
Exclusion
- Children with severe Asthmatic attack
- Allergy to any of the study drugs
- Diagnosis of Pneumocystis JiroveciPneumonia on therapeutic treatment
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2007
Estimated Enrollment :
348 Patients enrolled
Trial Details
Trial ID
NCT00372541
Start Date
September 1 2006
End Date
March 1 2007
Last Update
July 26 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Paediatrics and Child Health, Mulago Hospital
Kampala, East Africa, Uganda, 256
2
Department of Paediatrics and Child Health, Makerere University
Kampala, Kampala, Uganda, P O 7072
3
Department of paediatrics and child Health,Makerere university
Kampala, Kampala, Uganda, P O 7072
4
Department of Paediatrics and Child, Makerere University
Kampala, Kampala, Uganda, P O 7072